Cargando…
PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
Objective: To evaluate the efficacy of poly ADP ribose polymerase (PARP) inhibitors (PARPis) in breast and ovarian cancer with BRCA (BReast CAncer susceptibility gene) mutation (BRCAm). Methods: We conducted a meta-analysis of randomized controlled, phase II or III trials by searching of electronic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034970/ https://www.ncbi.nlm.nih.gov/pubmed/33705352 http://dx.doi.org/10.18632/aging.202724 |
_version_ | 1783676631366238208 |
---|---|
author | Shao, Fengping Duan, Yaoyun Zhao, Yunhe Li, Yinguang Liu, Jun Zhang, Cai He, Shanyang |
author_facet | Shao, Fengping Duan, Yaoyun Zhao, Yunhe Li, Yinguang Liu, Jun Zhang, Cai He, Shanyang |
author_sort | Shao, Fengping |
collection | PubMed |
description | Objective: To evaluate the efficacy of poly ADP ribose polymerase (PARP) inhibitors (PARPis) in breast and ovarian cancer with BRCA (BReast CAncer susceptibility gene) mutation (BRCAm). Methods: We conducted a meta-analysis of randomized controlled, phase II or III trials by searching of electronic databases from inception to September 1, 2020. The efficacy of PARPis measured by hazard ratios (HRs) and 95% confidence intervals (95% CIs) for progression free survival (PFS) and overall survival (OS) of patients. Results: By addition of PARPis to conventional therapy, breast or ovarian cancer patients carrying BRCAm significantly benefited PFS (breast cancer: HR 0.64, 95% CI=0.55-0.75, P<0.001; ovarian cancer: HR 0.33, 95% CI=0.27-0.42, P<0.001), but OS of patients did not increase significantly in these two cancer types (breast cancer: HR 0.87, 95% CI=0.76-1.01, P=0.065; ovarian cancer: HR 0.78, 95% CI=0.61-1.01, P=0.058). For ovarian cancer patients carrying BRCAm, the use of therapy with PARPis yielded longer PFS at the stage of newly diagnosed than the stage of recurrence (22.5 months vs 9.6 months). Conclusion: PARPis were beneficial to all with BRCAm, but they were "most" beneficial to the ovarian cancer subset when administered early after diagnosis, rather than after recurrence. |
format | Online Article Text |
id | pubmed-8034970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-80349702021-04-16 PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival Shao, Fengping Duan, Yaoyun Zhao, Yunhe Li, Yinguang Liu, Jun Zhang, Cai He, Shanyang Aging (Albany NY) Research Paper Objective: To evaluate the efficacy of poly ADP ribose polymerase (PARP) inhibitors (PARPis) in breast and ovarian cancer with BRCA (BReast CAncer susceptibility gene) mutation (BRCAm). Methods: We conducted a meta-analysis of randomized controlled, phase II or III trials by searching of electronic databases from inception to September 1, 2020. The efficacy of PARPis measured by hazard ratios (HRs) and 95% confidence intervals (95% CIs) for progression free survival (PFS) and overall survival (OS) of patients. Results: By addition of PARPis to conventional therapy, breast or ovarian cancer patients carrying BRCAm significantly benefited PFS (breast cancer: HR 0.64, 95% CI=0.55-0.75, P<0.001; ovarian cancer: HR 0.33, 95% CI=0.27-0.42, P<0.001), but OS of patients did not increase significantly in these two cancer types (breast cancer: HR 0.87, 95% CI=0.76-1.01, P=0.065; ovarian cancer: HR 0.78, 95% CI=0.61-1.01, P=0.058). For ovarian cancer patients carrying BRCAm, the use of therapy with PARPis yielded longer PFS at the stage of newly diagnosed than the stage of recurrence (22.5 months vs 9.6 months). Conclusion: PARPis were beneficial to all with BRCAm, but they were "most" beneficial to the ovarian cancer subset when administered early after diagnosis, rather than after recurrence. Impact Journals 2021-03-11 /pmc/articles/PMC8034970/ /pubmed/33705352 http://dx.doi.org/10.18632/aging.202724 Text en Copyright: © 2021 Shao et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Shao, Fengping Duan, Yaoyun Zhao, Yunhe Li, Yinguang Liu, Jun Zhang, Cai He, Shanyang PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival |
title | PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival |
title_full | PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival |
title_fullStr | PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival |
title_full_unstemmed | PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival |
title_short | PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival |
title_sort | parp inhibitors in breast and ovarian cancer with brca mutations: a meta-analysis of survival |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034970/ https://www.ncbi.nlm.nih.gov/pubmed/33705352 http://dx.doi.org/10.18632/aging.202724 |
work_keys_str_mv | AT shaofengping parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival AT duanyaoyun parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival AT zhaoyunhe parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival AT liyinguang parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival AT liujun parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival AT zhangcai parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival AT heshanyang parpinhibitorsinbreastandovariancancerwithbrcamutationsametaanalysisofsurvival |